Several versions of uPAR-targeting PET ligands based on the high affinity peptide ligand AE105 have been synthesized and tested preclinically in human xenograft mouse models and, recently, also in a first-ever clinical uPAR PET study in humans that included also patients with PC. This evidence concerns the gene PLAUR and pachyonychia congenita.